Establishment Labs Holdings Inc. (ESTA): what the price requires
At today's price, Establishment Labs Holdings Inc. (ESTA) is priced for today's economics sustained for ~18.1 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.
Generated: 2026-07-19 · Source: https://boothcheck.com/report/ESTA
Headline
| Field | Value |
|---|---|
| Ticker | ESTA |
| Company | Establishment Labs Holdings Inc. |
| Current price | $88.24/sh |
| Composition | EMEA 43% / Latin America 19% / Asia-Pacific 16% / North America 22% |
What The Price Requires (Inversion)
The assumption today's price embeds, recovered by inverting the valuation.
| Field | Value |
|---|---|
| Inversion basis | revenue-multiple |
| EV / sales paid | 13.5x |
| Steady-state operating margin assumed | 27.7% |
| Must persist for | 18.1y |
The company earns no operating profit yet; the inversion runs on the revenue multiple and an assumed steady-state margin.
Solve inputs: computed at a 13% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~2.7 years.
Reconcile: at the x-ray's 9.3% required return this reads ~9.7 years; the models below use their own rates.
How unusual the bet is: elevated
| Reference | Value |
|---|---|
| vs own history | +0.18σ |
| sustained it ~10 years at this level | 14% |
| implied end-window share | 0% |
Valuation X-Ray
Every valuation family lands below the price. The price therefore requires assumptions beyond what those standard frames encode.
How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.
| Family | Median price/FV | Models | Reads |
|---|---|---|---|
| Asset | — | 0 | — |
| Earnings | — | 0 | — |
| Relative | 2.88x | 2 | expensive |
| Growth | 1.74x | 2 | expensive |
Families that call it expensive: Relative, Growth
The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.6%); the inversion above states its own rate.
Per-Model Detail (n=4)
| Model | Family | FV | Price/FV | Applicable | Methodology |
|---|---|---|---|---|---|
| DCF Perpetual Growth | Growth | $0.00 | — | no | Negative/zero FCF — equity value floored at $0 |
| DCF Exit Multiple | Growth | $0.00 | — | no | Negative/zero FCF or EBITDA — equity value floored at $0 |
| Relative Valuation | Relative | $30.66 | 2.88x | yes | P/S fallback (negative EPS): Sector P/S 4.0x × TTM revenue — excluded from consensus |
| Simple DDM | Growth | — | — | no | — |
| Two-Stage DDM | Growth | — | — | no | — |
| Simple Excess Return | Asset | $0.49 | 180.08x | yes | Book value floor: BV/sh $0.49, ROE negative (excluded from median) |
| Two-Stage Excess Return | Asset | $0.44 | 200.55x | yes | Book value with convergence: BV/sh $0.49, ROE converges to ke (excluded from median) |
| Discounted Future Market Cap | Growth | $128.04 | 0.69x | yes | Rev $0.2B, growth 30% (input: historical growth; tapered), Terminal P/S: 9.2x / 11.5x / 13.8x (bear / base = today's held flat / bull, cap 12x) |
| Peter Lynch Fair Value | Relative | $0.00 | — | no | Negative/zero EPS — earnings-based value floored at $0 |
| Margin Trajectory | Growth | $31.60 | 2.79x | yes | Margin ramp: -19% → 12% over 7yr, rev growth 30% (input: historical growth; tapered) |
| Earnings Power Value | Earnings | — | — | no | — |
| Residual Income | Asset | — | — | no | — |
| Graham Number | Asset | — | — | no | — |
| EV/EBITDA Relative | Relative | — | — | no | — |
| FCF Yield | Earnings | — | — | no | — |
| SBC-Adj FCF Yield | Earnings | — | — | no | — |
| Ben Graham Formula | Earnings | — | — | no | — |
| ROIC-Justified P/B | Asset | — | — | no | — |
| P/Sales Sector | Relative | $30.66 | 2.88x | yes | Revenue $0.23B × sector P/S 4.0x |
| PEG Fair Value | Relative | — | — | no | — |
| Earnings Yield | Earnings | — | — | no | — |
| Funds From Operations Multiple | Relative | — | — | no | — |
| Clinical Phase NPV | Growth | — | — | no | — |
| Merton | Asset | — | — | no | — |
| V5 Mechanical | — | — | — | no | — |
Solvency
| Field | Value |
|---|---|
| Net debt | $190.5m |
| Interest coverage | -1.7x |
| Share count CAGR (dilution) | 5.4% |
| Burning cash | yes |
Operating profit is negative or near zero and the company has no demonstrated through-cycle (mid-cycle) operating margin to normalize against, so years-to-repay cannot be computed honestly.
Bullet Takeaways
- Establishment Labs is at a profitability inflection: revenue grew 44.7% to $59.9 million with a 70.7% gross margin, the operating loss narrowed sharply, and adjusted EBITDA turned positive for a third straight quarter, with management targeting free cash flow positivity in the second half of 2026.
- The biggest specific risk is the valuation: no standard method reaches the price, which embeds a swing from a negative 12% operating margin to roughly 28% sustained for nearly eighteen years, leaving no cushion if the U.S. ramp or margin transformation disappoints.
- What to watch next is the U.S. Motiva launch, U.S. revenue grew 216% year over year, and continued progress toward cash-flow breakeven against $68.1 million of cash and net debt of about $190 million.
Bull Case
The trajectory is the story, and it is inflecting in exactly the way a growth-stage medical device company is supposed to. Revenue grew 44.7% year over year to $59.9 million in the first quarter, and the losses are collapsing: loss from operations narrowed to $6.5 million from $16.9 million a year earlier, and adjusted EBITDA turned positive at $1.2 million, the third consecutive positive quarter. Gross margin expanded to 70.7%. For a company that is still reporting a GAAP operating loss, the right way to read those numbers is as a business approaching its profitability inflection: revenue is accelerating, the margin is high and rising, and the gap to breakeven is closing fast. Management expects free cash flow positivity in the second half of 2026.
The engine of the acceleration is the United States launch of the Motiva platform, the company's smooth-surface breast implant. U.S. revenue grew 216% over the prior-year quarter, with Motiva U.S. sales of $19.6 million, and the company surpassed its full-year surgeon-certification goal within the first quarter on stronger-than-expected demand. Entering the large, premium U.S. aesthetics market is the catalyst Establishment Labs spent years and regulatory effort to reach, and the early uptake suggests the product resonates. The company also benefits from a genuine safety differentiation: the 10-K notes "reports of breast implant-associated anaplastic large cell lymphoma linked to our competitors' products which have led to regulatory actions regarding macrotextured devices," a problem its smooth Motiva implants are designed to avoid.
The business is internationally diversified and improving its cash profile. Revenue spans EMEA, Latin America, Asia-Pacific, and now a fast-growing North America, so the company is not dependent on any single market. Cash use fell to $7.5 million from $21.2 million a year ago, and it ended the quarter with $68.1 million of cash. With the burn shrinking and adjusted EBITDA already positive, the runway question that haunts most loss-making growth companies is easing rather than tightening. For an investor willing to underwrite the inflection, the bull case is a high-gross-margin aesthetics franchise scaling into the U.S. with a safety-differentiated product, just as it crosses into cash generation.
Bear Case
The price has already written a decade and a half of flawless execution into the stock, and that is the assumption most likely to break. At the current quote the market is paying for Establishment Labs to swing from a negative 12% operating margin today to a roughly 28% margin and to sustain elevated growth for nearly eighteen years. That is an extraordinary distance to travel and an extraordinary duration to hold it. No standard valuation family reaches the price, not assets, not earnings power, not peer multiples, and not even the forward-growth lens. When every method falls short, the price is a bet beyond what any conventional frame supports, and the entire value rests on the U.S. launch compounding into durable, high-margin profitability without a stumble.
The competitive and regulatory risks are real and specific. Establishment Labs is entering a U.S. market dominated by far larger, better-capitalized competitors, and the aesthetics business is sensitive to discretionary consumer spending. The company's own filing warns that competition "may result in price reductions, reduced margins and our inability to gain or hold market share," which is precisely the dynamic that could derail the margin expansion the price requires. Medical devices also carry binary regulatory and safety risk: the same BIA-ALCL safety dynamics that currently favor smooth implants could shift, and any adverse safety finding or regulatory action would hit the product directly. The implant business is also subject to manufacturing supply-and-demand balance the company flags, where a demand decline leaves it unable to "reduce manufacturing expense" quickly.
The capital structure adds the financing dimension. The company carries net debt of about $190 million against $68.1 million of cash, interest coverage is negative because it is not yet profitable on a GAAP basis, and the share count has grown at a mid-single-digit annual rate, meaning existing holders have been diluted to fund the growth. Adjusted EBITDA is positive, but the GAAP operating line is still a loss, and the path to free-cash-flow positivity in the second half of 2026 is a plan, not yet a result. The bull case rests on that plan landing. The bear case is that a profitless company priced as if its U.S. ramp and margin transformation are already certain has no valuation cushion, so any disappointment, a slower U.S. ramp, a competitive price war, a safety scare, or a need to raise capital, reprices a stock that the methods say is worth a fraction of today's quote.
Valuation
Because Establishment Labs is not yet profitable, the price has to be read against revenue and a future margin rather than current earnings, and on that basis it is a demanding bet. The price embeds the operating margin swinging from a negative 12.4% today to roughly 27.7%, and it requires elevated growth to persist for close to eighteen years. That is among the longest-duration assumptions a stock can carry. The 70.7% gross margin shows the unit economics can support a high operating margin eventually, but the price assumes the company captures nearly all of that potential and holds it for a very long time.
The methods are unanimous that the price sits beyond standard valuation. The asset-value and earnings-power lenses do not even produce a value, because the company has thin book value and negative earnings, and the forward-growth and peer-multiple lenses, the two that do apply, both land well below the price. When no family reaches the quote, the price is not defended by any conventional frame; it is a pure expression of confidence in the U.S. ramp and the margin transformation. The right comparison is to other high-growth, pre-profit medical-device names, and even against that cohort the implied duration and margin endpoint are aggressive. The spread between the price and where the methods land is the size of the bet.
Solvency is the constraint that gives the thesis its deadline. The company carries about $190 million of net debt against $68.1 million of cash, and it is still burning on a GAAP basis, though the burn has shrunk sharply to $7.5 million in the quarter from $21.2 million a year earlier. Adjusted EBITDA has turned positive and management targets free-cash-flow positivity in the second half of 2026, which, if achieved, removes the financing overhang. Until then the runway and the path to cash generation are the load-bearing variables: the price assumes the company reaches self-funding profitability and then compounds at high margins for the better part of two decades, so the most decisive near-term evidence is the continued narrowing of the loss and the conversion of the U.S. launch momentum into the durable, profitable growth the valuation requires.
Catalysts
The Q1 2026 report, released in early May, was the central recent catalyst and it was a clear beat-and-raise that pushed the stock higher. Revenue rose 44.7% to $59.9 million, the operating loss narrowed to $6.5 million from $16.9 million, and adjusted EBITDA was positive at $1.2 million, the third consecutive positive quarter. Gross margin reached 70.7%, and management raised full-year revenue guidance to a $266.5 million to $268.5 million range. The combination of accelerating revenue and narrowing losses is the inflection investors had been waiting for.
The U.S. launch of the Motiva platform is the forward driver. U.S. revenue grew 216% over the prior-year quarter, with Motiva U.S. sales of $19.6 million, and the company surpassed its full-year surgeon-certification goal within the first quarter, a sign of strong early surgeon adoption. The U.S. market is the largest premium aesthetics opportunity the company has entered, and the certification pace is the leading indicator of how quickly the launch scales.
The most important forward milestone is the path to cash generation. The company ended the quarter with $68.1 million of cash, cut its cash use to $7.5 million from $21.2 million a year earlier, and reiterated that it expects positive adjusted EBITDA each quarter and free cash flow positivity in the second half of 2026. Into the coming quarters, the figures to watch are the continued U.S. ramp and surgeon adoption, the trajectory of the operating loss toward breakeven, and the cash position, since reaching self-funding profitability removes the financing overhang that hangs over a still-unprofitable growth company.
Peer Cohorts (Per Segment, With Filing Citations)
Establishment Labs (consolidated medical aesthetics) (reported)
- ATEC (Alphatec Holdings, Inc.)
- FY2025 10-K: 7-station cadaveric lab to enable visiting surgeons to gain deep practical experience with our procedural solutions and educate participants on our role in shaping innovation. 3 Table of Contents We believe that the surgeon relationships we create through our educational program support durable growth. The ATEC…
- FY2025 10-K: …reflect the Company's future ability to collect outstanding receivables or if the financial condition of customers were to deteriorate, resulting in impairment of their ability to make payments, an increase in the provision for doubtful accounts may be required. F- 12 Table of Contents The Company's accounts…
- AORT (ARTIVION, INC.)
- FY2025 10-K: …performance. Halting R&D efforts and clinical trials prematurely may lead to accelerated or unanticipated wind down costs. Even the successful commercialization of a new product or service in the medical industry can be characterized by slow growth and high costs associated with marketing, under-utilized production…
- FY2025 10-K: …storage of human organs and tissues. The activities we engage in require us to be either licensed or registered as a clinical laboratory or tissue bank under California, Delaware, Florida, Illinois, Maryland, New York, and Oregon law. We have such licenses or registrations, and we believe we are in compliance with…
- ATRC (AtriCure, Inc.)
- FY2025 10-K: …the body of clinical evidence. We believe publication of additional scientific evidence, in addition to robust ongoing research activities, will ultimately create an increased demand for our products. Build Physician and Societal Relationships. We have formed consulting relationships with cardiothoracic surgeons,…
- FY2025 10-K: …designed primarily for the surgical ablation of cardiac tissue, the exclusion of the left atrial appendage, and to block pain by temporarily ablating peripheral nerves. These devices are developed and marketed to a broad base of medical centers globally. Management considers all such sales to be part of the single…
- GKOS (GLAUKOS Corp)
- FY2025 10-K: …of corneal crosslinking therapies such as PeschkeTrade GmBH. Our anterior segment pipeline, if approved, would vastly expand our competition to numerous large companies such as AbbVie Inc., Alcon, Inc. and Johnson & Johnson, as well as some small companies that provide medical technology and pharmaceutical therapies…
- FY2025 10-K: …superiority supported by extensive data and innovative features that enhance patient benefit, product performance, and safety. The ophthalmic segment of the medical technology and pharmaceutical industries is dynamic and subject to significant change due to cost-of-care considerations, reimbursement levels,…
- LMAT (LEMAITRE VASCULAR, INC.)
- FY2025 10-K: …years and require renewal. As a holder of Chinese device licenses, we are subject to inspection by NMPA in both China and the United States. Our Shanghai offices were inspected by Shanghai Medical Products Authority in May 2024, and our Burlington facility was inspected by NMPA in October 2025, the results of which…
- FY2025 10-K: …historical experience and other assumptions as the basis for making estimates. We have described our significant accounting policies in Note 1 to our consolidated financial statements included in this Form 10-K. We believe the following critical accounting policies involve a significant level of estimation…
- PRCT (PROCEPT BioRobotics Corporation)
- FY2025 10-K: …regulatory clearance for the use of our products and Aquablation therapy for patients with prostate cancer, we expect we will be competing with additional companies. We compete, or may compete in the future, against other companies which have longer, more established operating histories and significantly greater…
- FY2025 10-K: …future commercial, regulatory and reimbursement efforts to drive growth. • Invest in research and development to drive continuous improvements and innovation. We are currently developing additional and next generation technologies to support and improve Aquablation therapy to further satisfy the evolving needs of…
- IRTC (iRhythm Holdings, Inc.)
- FY2025 10-K: . We do not anticipate meaningful revenue from any such opportunities to expand into the sleep apnea screening and diagnostics market for the foreseeable future. If we fail to capitalize on these opportunities, we may face threats from our competitors should they be able to commercialize products and services in the…
- FY2025 10-K: …arise from time to time in the future. For example, as discussed further in Note 8, Commitments and Contingencies, to the Consolidated Financial Statements, a putative securities class action lawsuit was filed against iRhythm Technologies and certain of its then current and former officer alleging violations of…
- TMDX (TransMedics Group, Inc.)
- FY2025 10-K: …MDR. Similar to the U.S. system, medical devices are classified into one of four classes based on risk: I, IIa, IIb and III, with class I representing the lowest risk products and class III the highest risk products. One of the most fundamental GSPRs is that a medical device must be designed and manufactured in such…
- FY2025 10-K: …Conformity assessment procedures involve an assessment of available clinical evidence, literature data for the product and post-market experience in respect of similar products already marketed. For all medical devices other than low risk devices ( i.e. , Class I non-sterile, non-measuring devices), a conformity…
Methodology Note
- Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
- Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
- Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
- Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.
Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.
Sources
Q1 2026 earnings release · Q1 2026 earnings call